Biofourmis vs Aidoc
A detailed comparison to help you choose between Biofourmis and Aidoc.
🏆
Verdict: Aidoc wins
Aidoc scores 4.2/5, edging out Biofourmis at 3.6/5. Hospital radiology departments and integrated health systems with meaningful acute imaging volumes that want one governed platform for many FDA-cleared triage algorithms instead of a stack of point solutions.
Biofourmis AI-powered patient monitoring and clinical insights for chronic disease management | Aidoc AI powered radiology image analysis platform | |
|---|---|---|
| Rating | 3.6 (1 review) | 4.2 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $10000/mo |
| Best For | Large health systems, IDNs and payers standing up hospital-at-home, post-acute or chronic-care monitoring programmes at scale who want FDA-cleared predictive analytics bundled with the clinical teams to act on it. | Hospital radiology departments and integrated health systems with meaningful acute imaging volumes that want one governed platform for many FDA-cleared triage algorithms instead of a stack of point solutions. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | api accessteam featuresgdpr compliant |
| Visit Biofourmis → | Visit Aidoc → |
Biofourmis
Pros
- + FDA-cleared analytics with Breakthrough Device Designation for BiovitalsHF — the strongest regulatory validation I have found in the RPM category.
- + The Biovitals engine models each patient against their own physiological baseline instead of population norms, which should meaningfully cut alert noise compared with threshold-based RPM (worth testing in any pilot).
- + It sells the escalation pathway with the software: virtual nursing, licensed navigators and in-home services (diagnostics, DME, meds, transport) orchestrated in one clinician dashboard — addressing the 2am-response gap that sinks most monitoring programmes.
- + Proven health-system deployments — AdventHealth acute care-at-home (January 2025), Lee Health hospital-at-home expansion (November 2024), plus UCI Health, Orlando Health, Augusta University Health and others named in company materials.
- + Device-agnostic sensor strategy with Epic EHR integration and a GE HealthCare partnership extending monitoring from hospital to home, so it fits existing clinical infrastructure rather than replacing it.
Cons
- - Zero commercial transparency: enterprise-only, no public pricing, custom contracts priced on patient volume and programme type — there is nothing to anchor a negotiation against.
- - The company has been through 120 layoffs (July 2023), a founder-CEO departure, an all-stock merger with CopilotIQ (October 2024) and a divestiture of its life-sciences arm (January 2025) — continuity risk on multi-year contracts.
- - Key performance claims (120+ biomarkers, deterioration detected days ahead, readmission reduction) are vendor-reported; I could not find independent head-to-head clinical evaluations.
- - No longer a clinical-trials vendor: biopharma buyers must now go to ActiGraph, which acquired Biofourmis Connect in January 2025.
- - It is a service-plus-software purchase — clinical staffing is embedded in the model, so the labour agreement carries as much delivery risk as the platform itself.
Aidoc
Pros
- + Widest FDA-cleared acute triage portfolio I have reviewed: 31 authorisations on the FDA's December 2025 list, plus the first multi-indication clearance covering 14 abdominal CT findings in one workflow
- + Multi-triage consolidation meaningfully reduces alert noise — one flagged study produces one stacked panel, not one pop-up per algorithm
- + Real-world deployment evidence: Mercy Health documented urgent case turnaround falling from 19.8h to 1.3h across 50+ hospitals, with 5,642 patients expedited from 50,749 flagged findings
- + Vendor-neutral aiOS layer lets a health system run third-party and Aidoc algorithms through one governance and notification stack (17 FDA-cleared algorithms deployed at Hartford HealthCare)
- + Care Coordination and Patient Management close the loop beyond triage: mobile alerts with image context, and report mining that routes incidental findings to facility-defined follow-up protocols
Cons
- - No public pricing, no trial, no free tier — third-party estimates of ~$50k/site/year baseline with $8k-$15k per extra module are unverifiable until you are deep in a sales process
- - Hospital-only: requires PACS/RIS/EHR integration work, so it is irrelevant to individual clinicians, small practices and low-volume facilities
- - 510(k) clearance for most modules does not itself require independent clinical performance data (per JAMA Network Open) — buyers should demand the study set, not just the clearance count
- - No public changelog for algorithm updates, which is a real gap for a system whose output feeds clinical decisions
- - Vendor performance figures (order-of-magnitude false-alert reduction, 1,600+ hospitals) are company claims I could not independently audit
Frequently Asked Questions
Which is better, Biofourmis or Aidoc?▼
Aidoc scores higher at 4.2/5 vs 3.6/5 for Biofourmis, making it the better-rated option in our comparison.
What is the difference between Biofourmis and Aidoc?▼
Biofourmis: Biofourmis runs remote patient monitoring and care-at-home programmes, combining wearable data with clinical analytics for health systems and life-science companies. Aidoc: Aidoc analyses medical imaging to flag urgent findings for radiologists and care teams, prioritising the cases that need attention first.
Is Biofourmis or Aidoc more affordable?▼
Biofourmis starts at €1000/mo, Aidoc starts at €10000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.